We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Thermo Fisher Scientific Signs New Agreements to Expand Oncomine Dx Target Test
Product News

Thermo Fisher Scientific Signs New Agreements to Expand Oncomine Dx Target Test

Thermo Fisher Scientific Signs New Agreements to Expand Oncomine Dx Target Test
Product News

Thermo Fisher Scientific Signs New Agreements to Expand Oncomine Dx Target Test

Credit: Thermo Fisher Scientific

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Thermo Fisher Scientific Signs New Agreements to Expand Oncomine Dx Target Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Thermo Fisher Scientific announced it has signed new agreements with Daiichi Sankyo and Takeda Pharmaceuticals designed to expand the clinical utility of Oncomine Dx Target Test in support of clinical trials and drug development programs at each of the firms. The agreements will focus on validating additional biomarkers and gene variants on the test and support Thermo Fisher’s commitment to further enable precision oncology.

Under the terms of the agreements, Thermo Fisher will retain global commercialization rights for the test and will lead all filings of supplemental premarket approvals (sPMA) in order to seek approval from the U.S. Food and Drug Administration (FDA). Expansion of Oncomine Dx Target Test aligns with the company’s strategic plan to further develop its test as a companion diagnostic (CDx) for multiple therapies.

“We are extremely pleased with the strong interest and commitment from our pharmaceutical partners who see the value of leveraging the expandability of Oncomine Dx Target Test,” said Joydeep Goswami, president of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific. “This unique feature can help expedite their drug development programs so that patients potentially benefit more quickly from the targeted therapies in the development pipeline.”

To date, Thermo Fisher has multiple active sPMA programs in place to expand Oncomine Dx Target Test, including an agreement announced today by Spectrum Pharmaceuticals, and another to add the ALK gene, which is nearing completion. The company entered into CDx agreements with Agios Pharmaceuticals last year to validate the test to identify IDH1 mutations in cholangiocarcinoma patients, and with Blueprint Medicines to identify RET fusions in non-small cell lung cancer (NSCLC).

Oncomine Dx Target Test is FDA approved to simultaneously report 23 genes clinically associated with NSCLC. Of those 23, three contain markers that are approved for use as a CDx for specific targeted therapies. It has also been adopted for use by several national reference laboratories, including LabCorp’s Diagnostics and Covance businesses, Quest Diagnostics, Cancer Genetics, Inc., and NeoGenomics Laboratories.

Since receiving FDA approval last year, Oncomine Dx Target Test has received positive reimbursement decisions from the Centers for Medicare and Medicaid Services and from the country’s largest commercial health insurers, including CIGNA, Aetna, UnitedHealthcare and the Centers for Medicare and Medicaid Services – making the test available to more than 160 million lives in the United States.
Advertisement